Project Oncology®

Could lower doses of radiation help optimize immune response in mesothelioma? Dr. John Cho joins us to explain how tailoring radiation to a tumor’s inflammatory and immunogenic characteristics could help modulate antitumor immunity while reducing the potential for fibrosis and treatment-related toxicity. Dr. Cho is a radiation oncologist at the Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto, and he spoke about this topic at the 2026 World Conference on Lung Cancer.

The treatment landscape for ALK+ metastatic non-small cell lung cancer (mNSCLC) is continuing to evolve, with durable outcomes from frontline ALK inhibition and emerging therapies offering new possibilities across disease settings. Join Dr. Angel Qin, Clinical Associate Professor of Internal Medicine at the University of Michigan Medical School, as she examines the evidence on current and emerging treatment options for this population.

Even with increasingly effective targeted therapies for ALK+ metastatic non-small cell lung cancer (mNSCLC), unanswered questions remain, especially when a patient's disease progresses or treatment becomes difficult to tolerate. In this program, Dr. Angel Qin looks beyond current care strategies to consider where the field is headed, from overcoming resistance to investigating entirely different ways of extending disease control. Dr. Qin is a Clinical Associate Professor of Internal Medicine at the University of Michigan Medical School.

Checkpoint inhibitors have shown limited efficacy in ALK+ metastatic non-small cell lung cancer (mNSCLC), but could a different immunologic strategy complement targeted therapy? Dr. Angel Qin discusses the rationale for ALK vaccines and explains how harnessing an ALK-specific immune response may help extend the durability of ALK TKI therapy. She's a Clinical Associate Professor of Internal Medicine at the University of Michigan Medical School.

Despite advances in ALK inhibition, resistance remains an important challenge in metastatic ALK+ non-small cell lung cancer (NSCLC). Dr. Alice Shaw, Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School, explores patterns of disease progression, emerging on- and off-target resistance mechanisms, and the potential role of combination approaches in overcoming resistance.

In metastatic non-small cell lung cancer (mNSCLC), resistance to ALK TKIs can differ depending on which therapies a patient has previously received, with important implications for next steps in treatment. Dr. Alice Shaw explains how treatment history and molecular testing at progression can help identify ALK-dependent and other actionable resistance mechanisms to help inform next-line therapy. She's the Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School.

Despite major advances in targeted therapy for ALK+ metastatic non-small cell lung cancer (mNSCLC), challenges remain in achieving durable responses and preventing treatment resistance. Hear from Dr. Alice Shaw as she explores key unanswered questions and emerging research aimed at addressing gaps in care for these patients. Dr. Shaw is the Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School.

As CAR T-cell therapy options expand for relapsed or refractory (R/R) multiple myeloma, comparative data may help clinicians weigh efficacy and safety when selecting treatment. One recent matching-adjusted indirect comparison of anitocabtagene autoleucel and ciltacabtagene autoleucel drew on data from the iMMAGINE-1 and CARTITUDE-1 trials to evaluate response and safety outcomes, including cytokine release syndrome, ICANS, infections, and non-relapse mortality. To learn about the findings, their clinical implications, and important limitations of the analysis, Dr. Charles Turck speaks with Dr. Krina Patel, Professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center in Houston. She also presented these data at the 2026 International Myeloma Society Annual Meeting.

A recent analysis used matching-adjusted indirect comparisons to evaluate anitocabtagene autoleucel, teclistamab, and talquetamab for relapsed or refractory (R/R) multiple myeloma, drawing on data from the iMMAGINE-1, MajesTEC-1, and MonumenTAL-1 trials. The analysis compared efficacy and safety outcomes across these CAR T-cell and bispecific therapies, including overall response, depth of response, MRD negativity, cytokine release syndrome, ICANS, infections, and non-relapse mortality. To explore the findings, their potential clinical implications, and key limitations of these indirect comparisons, Dr. Charles Turck speaks with Dr. Krina Patel, Professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center in Houston. She also presented these data at the 2026 International Myeloma Society Annual Meeting.

For patients who smoke or have a history of smoking, seeking lung cancer screening can mean confronting more than the fear of a diagnosis; it can also mean anticipating blame and judgment. Dr. Lisa Carter-Bawa joins us to share how tobacco-related stigma and nihilism can discourage screening, honest conversations, and follow-up care. Learn how approaching patients with greater awareness and compassion can help create a more supportive path to early detection. Dr. Carter-Bawa is the Director of the Cancer Prevention Precision Control Institute at the Hackensack Meridian Health Center for Discovery and Innovation and a Co-Leader of the Cancer Prevention and Control Program and the Deputy Associate Director of Community Outreach and Engagement for the Georgetown University Lombardi Comprehensive Cancer Center. She spoke about this topic at the 2026 World Conference on Lung Cancer.